AVITA Medical, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AVITA Medical, Inc. on June 5, 2026. The report details the execution of a material definitive agreement following shareholder approval at the 2026 Annual Meeting of Stockholders held on June 3, 2026.
Key Financial Metrics and Agreements
The filing concerns a senior secured credit facility with Perceptive Credit Holdings V, LP. Key terms include:
- Total Facility Size: Up to $60 million aggregate principal amount.
- Initial Drawdown: $50 million made available on the closing date (January 2026).
- Additional Commitment: $10 million available at the Company's discretion by March 31, 2027, subject to a net revenue requirement.
- Warrant Issuance: Issuance of a warrant to purchase up to 500,000 shares of Common Stock at an exercise price of $3.4019 per share.
- Contingent Warrant Shares: An additional 150,000 shares will vest if the Additional Commitment Amount is incurred.
The filing does not provide specific values for revenue, profit, cash flow, margins, or current debt levels beyond the credit facility terms.
Material Changes
The primary material change is the formal issuance of the Warrant to Perceptive Credit Holdings V, LP on June 5, 2026, following the requisite shareholder approval. This action finalizes the equity component of the credit agreement previously disclosed in January 2026.
Outlook, Risks, and Unusual Items
Management Commentary: The Company has satisfied the shareholder approval condition precedent for the warrant issuance. The warrant shares are registered under a Form S-3 Registration Statement.
Risks and Contingencies: The availability of the additional $10 million commitment is contingent upon the satisfaction of a specific net revenue requirement. The filing includes standard legal disclaimers regarding the offer and sale of securities in jurisdictions where such offers may be unlawful.
Investor Verification Checklist
- Verify the exact net revenue requirement threshold needed to trigger the $10 million Additional Commitment Amount.
- Confirm the vesting schedule and expiration date of the 500,000 initial warrant shares and the 150,000 contingent shares.
- Review the full text of the Warrant Certificate (Exhibit 4.1) for specific covenants, dilution protections, or early exercise provisions.
- Assess the impact of the $3.4019 exercise price relative to the current market price of AVITA Medical's common stock.